Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors

Medical Microbiology and Immunology

Volumn 201, Issue 2, 2012, Pages 213-218

  Knops, Elena ^a   Brakier Gingras, Léa ^b   Schülter, Eugen ^a   Pfister, Herbert ^a   Kaiser, Rolf ^a   Verheyen, Jens ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Drug resistance; Frameshift; Gag mutations; HIV 1

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; POL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION;

DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE;

EID: 84863426700     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-011-0224-z     Document Type: Article

References (29)

1. Knops E, Kemper I, Schulter E, Pfister H, Kaiser R, Verheyen J (2010) The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V. Aids 24(5):779-781. doi:10.1097/QAD.0b013e328336784d
2. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Krausslich HG, Brun-Vezinet F, Boucher CA (2007) A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4(1):e36
3. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Krausslich HG, Hance AJ, Clavel F (2009) Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 5(3):e1000345. doi:10.1371/journal.ppat.1000345
4. Prabu-Jeyabalan M, Nalivaika EA, King NM, SchiVer CA (2004) Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drugresistant mutation in viral protease. J Virol 78(22):12446-12454
5. Ho SK, Coman RM, Bunger JC, Rose SL, O'Brien P, Munoz I, Dunn BM, Sleasman JW, Goodenow MM (2008) Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6 (Gag)/p6 (Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant eVect on replicative fitness and drug response. Virology 378 (2):272-281. doi:10.1016/j.virol.2008.05.029
6. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM (2010) Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. Aids 24(11):1651-1655
7. Knops E, Daumer M, Awerkiew S, Kartashev V, Schulter E, Kutsev S, Brakier-Gingras L, Kaiser R, Pfister H, Verheyen J (2010) Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimicrob Chemother 65(7):1472-1476. doi:10.1093/jac/dkq129
8. Shehu-Xhilaga M, Crowe SM, Mak J (2001) Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol 75(4):1834-1841. doi:10.1128/JVI.75.4.1834-1841.2001
9. Callebaut C, Stray K, Tsai L, Xu L, Lee W, Cihlar T (2007) In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. In: XVI International HIV drug resistance workshop, Barbados, West Indies, 12-16 June 2007. Antiviral Therapy, 16, p S18
10. Verheyen J, Schweitzer F, Harrer EG, Knops E, Mueller SM, Daumer M, Eismann K, Bergmann S, Spriewald BM, Kaiser R, Harrer T (2010) Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates. Antivir Ther 15(6):907-912. doi:10.3851/IMP1640
11. Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D (2010) Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIVinfected patients. Antimicrob Agents Chemother 54(7):2910-2919. doi:10.1128/AAC.00194-10
12. Girnary R, King L, Robinson L, Elston R, Brierley I (2007) Structurefunction analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors. J Gen Virol 88(Pt 1):226-235
13. Doyon L, Payant C, Brakier-Gingras L, Lamarre D (1998) Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 72(7):6146-6150
14. Hill MK, Shehu-Xhilaga M, Crowe SM, Mak J (2002) Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J Virol 76(22):11245-11253
15. * mutations on viral protease-mediated Gag processing. J Gen Virol 87(Pt 7):2041-2046. doi:10.1099/vir.0.81601-0
16. * in viral replication. J Virol 83(14):7210-7220. doi:10.1128/JVI.02603-08
17. Schulter E, Oette M, Balduin M, Reuter S, Rockstroh J, Fatkenheuer G, Esser S, Lengauer T, Agacfidan A, Pfister H, Kaiser R, Akgul B (2011) HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany. Med Microbiol Immunol 200:219-223. doi:10.1007/s00430-011- 0193-2
18. Reuter S, Oette M, Wilhelm FC, Beggel B, Kaiser R, Balduin M, Schweitzer F, Verheyen J, Adams O, Lengauer T, Fatkenheuer G, Pfister H, Haussinger D (2011) Prevalence and characteristics of hepatitis B and C virus infections in treatment-naive HIV-infected patients. Med Microbiol Immunol 200(1):39-49. doi:10.1007/s00430-010-0172-z
19. Sierra S, Lubke N, Walter H, Schulter E, Reuter S, Fatkenheuer G, Bickel M, Silva HD, Kaiser R, Esser S (2011) The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in diVerent non-B subtypes. Med Microbiol Immunol 200:225-232. doi:10.1007/s00430-011-0194-1
20. Oette M, Kaiser R, Daumer M, Akbari D, Fatkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmaloer D, Gobels K, Vogt C, Wettstein M, Haussinger D (2004) Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 9(5):273-278
21. Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fatkenheuer G, Rockstroh JK, Schuldenzucker U, HoVmann D, Pfister H, Kaiser R (2006) Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapyexperienced patients. Antivir Ther 11(7):879-887
22. Dulude D, Baril M, Brakier-Gingras L (2002) Characterization of the frameshift stimulatory signal controlling a programmed-1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids Res 30(23):5094-5102
23. Dulude D, Berchiche YA, Gendron K, Brakier-Gingras L, Heveker N (2006) Decreasing the frameshift eYciency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1. Virology 345(1):127-136. doi:10.1016/j.virol.2005.08.048
24. Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF, Atkins JF (1998) A dual-luciferase reporter system for studying recoding signals. RNA 4(4):479-486
25. Verheyen J, Knops E, Kupfer B, Hamouda O, Somogyi S, Schuldenzucker U, HoVmann D, Kaiser R, Pfister H, Kucherer C (2009) Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients. J Infect 58(1):61-67. doi:10.1016/j.jinf.2008.11.009
26. van Maarseveen NM, Wensing AM, de Jong D, Taconis M, BorleVs JC, Boucher CA, Nijhuis M (2007) Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory Wxation. J Infect Dis 195(3):399-409
27. Telenti A, Martinez R, Munoz M, Bleiber G, Greub G, Sanglard D, Peters S (2002) Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J Virol 76(15):7868-7873
28. Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M (2010) High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. Aids 24(5):669-673. doi:10.1097/QAD.0b013e32833160fa
29. Heider D, Verheyen J, HoVmann D (2010) Predicting Bevirimat resistance of HIV-1 from genotype. BMC Bioinformatics 11:37. doi:10.1186/1471-2105-11-37